Acceptance of oral chemotherapy in breast cancer patients - a survey study

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Schott, Sarah ^a   Schneeweiss, Andreas ^a   Reinhardt, Judith ^a   Bruckner, Thomas ^b   Domschke, Christoph ^a   Sohn, Christof ^a   Eichbaum, Michael H ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Institute for Medical Biometry and Informatics   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CHI SQUARE TEST; CONTROLLED STUDY; COPING BEHAVIOR; CORRELATION COEFFICIENT; DRUG EFFICACY; HUMAN; INTRAVENOUS ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL CHEMOTHERAPY; ORAL DRUG ADMINISTRATION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PROSPECTIVE STUDY; QUESTIONNAIRE; SOCIAL SUPPORT; STATISTICS; TREATMENT INDICATION; ADAPTIVE BEHAVIOR; BREAST TUMOR; CARCINOMA; COMPARATIVE STUDY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PSYCHOLOGICAL ASPECT;

ANTINEOPLASTIC AGENT;

ADAPTATION, PSYCHOLOGICAL; ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT COMPLIANCE; QUESTIONNAIRES;

EID: 79953905153     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-129     Document Type: Article

References (52)

1. WHO Cancer. Fact Sheet N°297 2009, WHO.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108. 10.3322/canjclin.55.2.74, 15761078.
3. Llombart-Cussac A. Improving decision-making in early breast cancer: who to treat and how?. Breast Cancer Res Treat 2008, 112(Suppl 1):15-24. 10.1007/s10549-008-0234-8, 19082929.
4. Navarro RP, Morrow T, Baran R. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy. Manag Care Interface 2002, 15(7):55-62.
5. Avis NE, Crawford S, Manuel J. Quality of life among younger women with breast cancer. J Clin Oncol 2005, 23(15):3322-3330. 10.1200/JCO.2005.05.130, 15908646.
6. Siddiqi A, Given CW, Given B, Sikorskii A. Quality of life among patients with primary, metastatic and recurrent cancer. Eur J Cancer Care (Engl) 2009, 18(1):84-96. 10.1111/j.1365-2354.2008.01021.x, 19484831.
7. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH. On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983, 19(2):203-208. 10.1016/0277-5379(83)90418-2, 6681766.
8. Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 1992, 35(12):1505-1509. 10.1016/0277-9536(92)90053-S, 1283035.
9. O'Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 2002, 87(9):933-937. 2364332, 12434279.
10. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002, 2(12):927-937. 10.1038/nrc952, 12459731.
11. Fallowfield L, Atkins L, Catt S, Cox A, Coxon C, Langridge C, Morris R, Price M. Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 2006, 17(2):205-210. 10.1093/annonc/mdj044, 16239231.
12. Yabroff KR, Warren JL, Knopf K, Davis WW, Brown ML. Estimating patient time costs associated with colorectal cancer care. Med Care 2005, 43(7):640-648. 10.1097/01.mlr.0000167177.45020.4a, 15970778.
13. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998, 16(7):2557-2567.
14. Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, Langbaum TS, Leedy RD, Muller RJ, Newcomer LN, et al. NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw 2008, 6(Suppl 3):S1-14.
15. Schwartzberg LS, Cobb P, Walker MS, Stepanski EJ, Houts AC. Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer. Support Care Cancer 2009,
16. Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, Imadalou K, Trillet-Lenoir V. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 2003, 21(1):35-40.
17. Trillet-Lenoir VSH, Delozier T, Koralewski P, Ruiz Simon A, Lichinister M, Gedouin D, Amadori D. Oral vinorelbine in metastatic breast cancer: long term results of 2 phase II studies. Eur J Cancer 2004, 2(3):137. abstract 279.
18. Gampenrieder SP, Bartsch R, Matzneller P, Pluschnig U, Dubsky P, Gnant MX, Zielinski CC, Steger GG. Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer. Breast Care (Basel) 2010, 5(3):158-162. 10.1159/000314214, 2931054, 21048830.
19. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997, 15(1):110-115.
20. Twelves C, Gollins S, Grieve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006, 17(2):239-245. 10.1093/annonc/mdj023, 16344278.
21. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004, 90(6):1190-1197. 10.1038/sj.bjc.6601676, 2409640, 15026800.
22. Ward S, Kaltenthaler E, Cowan J, Brewer N. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2003, 7(32):1-93.
23. James RDSB, Fischer von Weikerstahl L, Garcia Palomo A, Gebbia V, O Hansen AM, Meldgaard P, Welt A, Vaissière N. Improving chemotherapy capacity by switching from intravenous to oral vinorelbine: tamino, an international time and motion audit. ECCO 15 - ESMO 34 2009, poster number 83.
24. Catania C, Didier F, Leon ME, Sbanotto A, Mariani L, Nole F, Leida E, Rocca A, De Pas T, Goldhirsch A. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Cancer Res Treat 2005, 92(3):265-272. 10.1007/s10549-005-3376-y, 16155797.
25. Jensen LH, Osterlind K, Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer 2008, 62(1):85-91. 10.1016/j.lungcan.2008.02.009, 18372075.
26. Findlay M, von Minckwitz G, Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 2008, 19(2):212-222. 10.1093/annonc/mdm285, 18006898.
27. Morgan GJ, Krishnan B, Jenner M, Davies FE. Advances in oral therapy for multiple myeloma. Lancet Oncol 2006, 7(4):316-325. 10.1016/S1470-2045(06)70657-X, 16574547.
28. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002, 13(1):73-80. 10.1093/annonc/mdf013, 11863115.
29. Fumoleau P, Largillier R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Cure H, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004, 40(4):536-542. 10.1016/j.ejca.2003.11.007, 14962720.
30. Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm 2007, 64(9 Suppl 5):S4-7. 10.2146/ajhp070035, 17468157.
31. Maserat E. Information communication technology: new approach for rural cancer care improvement. Asian Pac J Cancer Prev 2008, 9(4):811-814.
32. Baird G, Flynn R, Baxter G, Donnelly M, Lawrence J. Travel time and cancer care: an example of the inverse care law?. Rural Remote Health 2008, 8(4):1003.
33. Le Lay K, Myon E, Hill S, Riou-Franca L, Scott D, Sidhu M, Dunlop D, Launois R. Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system. Eur J Health Econ 2007, 8(2):145-151. 10.1007/s10198-006-0034-1, 17333088.
34. Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002, 94(9):652-661.
35. Sharma S. Patient selection for oral chemotherapy. Oncology (Williston Park) 2001, 15(1 Suppl 2):33-35.
36. Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H. Answering patients' needs: oral alternatives to intravenous therapy. Oncologist 2001, 6(Suppl 4):12-16. 10.1634/theoncologist.6-suppl_4-12, 11585969.
37. Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol 2004, 5(8):489-496. 10.1016/S1470-2045(04)01528-1, 15288238.
38. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009, 360(20):2055-2065. 10.1056/NEJMoa0810266, 19439741.
39. Nole F, Crivellari D, Mattioli R, Pinotti G, Foa P, Verri E, Fougeray R, Brandely M, Goldhirsch A. Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 2009, 64(4):673-680. 10.1007/s00280-008-0915-3, 19184601.
40. Tubiana-Mathieu N, Bougnoux P, Becquart D, Chan A, Conte PF, Majois F, Espie M, Morand M, Vaissiere N, Villanova G. All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial. Br J Cancer 2009, 101(2):232-237. 10.1038/sj.bjc.6605156, 2720198, 19584872.
41. Rowinsky EK, Lucas VS, Hsieh AL, Wargin WA, Hohneker JA, Lubejko B, Sartorius SE, Donehower RC. The effects of food and divided dosing on the bioavailability of oral vinorelbine. Cancer Chemother Pharmacol 1996, 39(1-2):9-16. 10.1007/s002800050532, 8995494.
42. Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 2001, 12(11):1643-1649. 10.1023/A:1013180903805, 11822766.
43. Bugat R, Variol P, Roche H, Fumoleau P, Robinet G, Senac I. The effects of food on the pharmacokinetic profile of oral vinorelbine. Cancer Chemother Pharmacol 2002, 50(4):285-290. 10.1007/s00280-002-0475-x, 12357302.
44. Bourgeois H, Vermorken J, Dark G, Jones A, Fumoleau P, Stupp R, Tourani J, Brain E, Nguyen L, Lefresne F, et al. Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours. Cancer Chemother Pharmacol 2007, 60(3):407-413. 10.1007/s00280-007-0510-z, 17541591.
45. Pfeiffer P, Mortensen JP, Bjerregaard B, Eckhoff L, Schonnemann K, Sandberg E, Aabo K, Jakobsen A. Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. Eur J Cancer 2006, 42(16):2738-2743. 10.1016/j.ejca.2006.06.027, 17011184.
46. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002, 38(3):349-358. 10.1016/S0959-8049(01)00371-9, 11818199.
47. Lima AP, del Giglio A. Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience. Eur J Cancer Care (Engl) 2005, 14(2):151-154. 10.1111/j.1365-2354.2005.00531.x, 15842464.
48. Leonard RC, Cameron DA, Anderson A, Ostrowski J, Howell A. Idarubicin and cyclophosphamide--an active oral chemotherapy regimen for advanced breast cancer. Crit Rev Oncol Hematol 2000, 33(1):61-66. 10.1016/S1040-8428(99)00042-6, 10714963.
49. Lebovits AH, Strain JJ, Schleifer SJ, Tanaka JS, Bhardwaj S, Messe MR. Patient noncompliance with self-administered chemotherapy. Cancer 1990, 65(1):17-22. 10.1002/1097-0142(19900101)65:1<17::AID-CNCR2820650106>3.0.CO;2-I, 2293862.
50. Faithfull S, Deery P. Implementation of capecitabine (Xeloda) into a cancer centre: UK experience. Eur J Oncol Nurs 2004, 8(Suppl 1):S54-62. 10.1016/j.ejon.2004.06.009, 15341882.
51. Chau I, Legge S, Fumoleau P. The vital role of education and information in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 2004, 8(Suppl 1):S41-53. 10.1016/j.ejon.2004.06.008, 15341881.
52. Schott H, Schott S, Schwendener RA. Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding. Bioorg Med Chem 2009, 17(19):6824-6831. 10.1016/j.bmc.2009.08.033, 19744858.